11-2013

Extracellular Calcium Modulates Actions of Orthosteric and Allosteric Ligands on Metabotropic Glutamate Receptor 1alpha

Jason Y. Jiang
Georgia State University

Mulpuri Nagaraju
Georgia State University, mulpurinagaraju@gsu.edu

Rebecca C. Meyer
Emory University, rebecca.meyer@tn.gov

Li Zhang
Georgia State University

Donald Hamelberg
Georgia State University, dhamelberg@gsu.edu

See next page for additional authors

Recommended Citation

Authors

Jason Y. Jiang, Mulpuri Nagaraju, Rebecca C. Meyer, Li Zhang, Donald Hamelberg, Randy A. Hall, Edward M. Brown, P. Jeffrey Conn, and Jenny J. Yang

EXTRACELLULAR CALCIUM MODULATES ACTIONS OF ORTHOSTERIC AND ALLOSTERIC LIGANDS ON METABOTROPIC GLUTAMATE RECEPTOR 1 ALPHA

Jason Y. Jiang[1], Mulpuri Nagaraju[1], Rebecca C. Meyer[2], Li Zhang[1], Donald Hamelberg[1], Randy A. Hall[2], Edward M. Brown[3], P. Jeffrey Conn[4] and Jenny J. Yang[1*]

[1]Department of Chemistry, Center for Drug Design and Advanced Biotechnology, Georgia State University, Atlanta, Georgia 30303
[2]Department of Pharmacology, Emory University School of Medicine, Atlanta, Georgia 30322
[3]Division of Endocrinology, Diabetes and Hypertension, Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115
[4]Department of Pharmacology, Vanderbilt University Medical Center, Nashville, TN 37232

*Running Title: *Ca^{2+} modulates mGluR1ligands*

To whom correspondence should be addressed: Dr. Jenny, J. Yang, Department of Chemistry, Georgia State University, 552 Natural Science Center, Atlanta, GA 30303; Tel.: 404-413-5520; Fax: (404) 413-5551; E-Mail: jenny@gsu.edu

Keywords: Calcium; Calcium binding proteins; Drug discovery; G protein coupled receptors (GPCR); Glutamate receptors metabotropic; allosteric modulators; orthosteric agonist; orthosteric antagonist

Background: Extracellular Ca^{2+} alters mGluR1α activity, but by an unknown mechanism.

Results: Mutations in predicted Ca^{2+}-binding sites modulated the potency of both orthosteric and allosteric modulators.

Conclusion: Ca^{2+} binding exerts multiple effects on mGluR1α.

Significance: Understanding how Ca^{2+} modulates mGluR1α activity could facilitate development of isoform-selective drugs and/or elucidate how to tune the actions of available drugs.

SUMMARY: Metabotropic glutamate receptor 1α (mGluR1α), a member of the family C G protein-coupled receptors (GPCRs), is emerging as a potential drug target for various disorders including chronic neuronal degenerative diseases. In addition to being activated by glutamate, mGluR1α is also modulated by extracellular Ca^{2+}. However, the underlying mechanism is unknown. Moreover, it has long been challenging to develop receptor-specific agonists due to homologies within the mGluR family, and the Ca^{2+}-binding site(s) on mGluR1α may provide an opportunity for receptor-selective targeting by therapeutics. In the present study, we show that our previously predicted Ca^{2+}-binding site in the hinge region of mGluR1α is adjacent to the site where orthosteric agonists and antagonists bind on the extracellular domain of the receptor. Moreover, we have found that extracellular Ca^{2+} enhances mGluR1α-mediated intracellular Ca^{2+} responses evoked by the orthosteric agonist, L-quisqualate. Conversely, extracellular Ca^{2+} diminishes the inhibitory effect of the mGluR1α orthosteric antagonist, (s)-MCPG. In addition, selective positive (Ro 67-4853) and negative (CPCCOEt) allosteric modulators of mGluR1α potentiate and inhibit responses to extracellular Ca^{2+}, respectively, in a manner similar to their effects on the response of mGluR1α to glutamate. Mutations at residues predicted to be involved in Ca^{2+}-binding, including E325I, have significant effects on the modulation of responses to the orthosteric agonist, L-quisqualate, and the allosteric modulator Ro 67-4853 by extracellular Ca^{2+}. These studies reveal that binding of extracellular Ca^{2+} to the predicted Ca^{2+}-binding site in the ECD of mGluR1α modulates not only glutamate-evoked signaling but also the actions of both orthosteric ligands and allosteric modulators on mGluR1α.

The eight subtypes of metabotropic glutamate receptors (mGluRs) belong to family C of the G protein-coupled receptors (GPCRs) and possess a large extracellular domain (ECD), a transmembrane domain (TMD) and cytosolic C-terminal tail. The mGluRs are widely expressed in the central nervous system and play critical roles in regulating neuronal excitability and synaptic plasticity at both excitatory and inhibitory synapses (1). Extensive structural studies have revealed that the endogenous agonist, L-Glutamate (L-Glu), the major excitatory neurotransmitter in the central nervous system, binds at the hinge region of the ECD within the receptor's Venus fly trap (VFT) motif to activate the protein. This subsequently stimulates phospholipase C (PLC) and leads to accumulation of inositol trisphosphate (IP_3) and an increase of intracellular calcium concentration ($[Ca^{2+}]_i$) (2-4).

In recent years, mGluRs have received increasing interest as potential drug targets for the treatment of a range of psychiatric and neurological diseases (5) (Fig 1). The ligands targeting mGluRs can be classified as orthosteric agonists and antagonists as well as allosteric modulators. Orthosteric

2

agonists and antagonists induce and attenuate, respectively, the activity of the receptor by competitively binding to the L-Glu binding pocket. L-Quisqualate (L-Quis), the most potent agonist of mGluR1 reported to date (6,7), has been speculated to share nearly the same binding pocket as L-Glu (8,9). In contrast, (s)-MCPG is an analog of L-Glu and is a non-selective competitive antagonist that has been shown to occupy the L-Glu binding pocket, thereby blocking the function of group I/II members in the mGluR family (10). On the other hand, allosteric modulators bind to sites other than the orthosteric center to affect the activity of the receptor. Ro 67-4853 is a positive allosteric modulator (PAM) of mGluR1 that enhances the potency of L-Glu by interacting with the TMD of the receptor. CPCCOEt is a negative allosteric modulator (NAM) that inhibits the activation of mGluR1 by L-Glu by specifically binding to a site that involves the third extracellular loop of mGluR1α (11).

Like other members of the family C GPCRs such as the calcium-sensing receptor (CaSR), mGluR1α senses $[Ca^{2+}]_o$ using the extracellular domain (12,13). By transient expression of mGluR1α in oocytes, Kubo et al. demonstrated that mGluR1-mediated activation of Ca^{2+}-activated Cl^- channels is modulated by $[Ca^{2+}]_o$ in addition to L-Glu (4). Purkinje cells from mGluR1 knockout mice lose sensitivity to $[Ca^{2+}]_o$, with this sensitivity to $[Ca^{2+}]_o$ being restored after mGluR1 was genetically reintroduced into the mice (14). There are sparse reports of $[Ca^{2+}]_o$ affecting the action of various classes of compounds acting on mGluRs (15). However, it is not clear how $[Ca^{2+}]_o$ is able to modulate the activity of mGluR1 or the actions of various mGluR1 ligands, and no Ca^{2+}-binding sites have been identified in the 15 structures solved by X-ray crystallography to date (www.pdb.org).

Using our recently developed computational algorithm, we have identified a novel potential $[Ca^{2+}]_o$-binding site within the hinge region of the ECD of mGluR1α, adjacent to the reported L-Glu-binding site (16,17). It is comprised of D318, E325, D322, and the carboxylate side chain of the natural agonist, L-Glu. The carboxylate side chains of both L-Glu and D318 are involved in both L-Glu- and $[Ca^{2+}]_o$-binding. Our previous mutagenesis study indicated that binding of L-Glu and Ca^{2+} to their distinct but partially-overlapping binding sites synergistically modulates mGluR1α-mediated activation of intracellular Ca^{2+} ($[Ca^{2+}]_i$ signaling. Mutating the L-Glu-binding site completely abolished L-Glu signaling, while leaving its Ca^{2+}-sensing capability largely intact. Mutating predicted Ca^{2+}-binding residues not only abolished or significantly reduced the sensitivity of mGluR1α to $[Ca^{2+}]_o$ but also, in some cases, to L-Glu (18).

In the present study, we first demonstrated that our predicted Ca^{2+}-binding site is adjacent to the orthosteric agonist and antagonist interaction sites. We then examined the role of $[Ca^{2+}]_o$ in modulating the actions of different orthosteric ligands acting on mGluR1α, including L-Quis, (s)-MCPG, as well as reciprocal interactions between Ca^{2+} and the mGluR1 allosteric modulators, Ro 67-4853 and CPCCOEt. Our results suggest $[Ca^{2+}]_o$ modulates the sensitivity of mGluR1α to not only orthosteric agonists and antagonists but also to allosteric modulators, likely by interacting with the predicted $[Ca^{2+}]_o$-binding site in the ECD of the receptor.

EXPERIMENTAL PROCEDURES

Dock L-Quis to ECD-mGluR1α using Autodock-vina and hinge motion analysis. To elucidate L-Quis's binding to the ECD of mGluR1α, L-Quis was docked into the crystal structure (1EWK). After removing

3

the coordinates of the bound endogenous ligand, L-Glu, the pdb file was loaded into Autodock tools to add polar hydrogen atoms and choose the docking center and grid box. The docking work was carried out by Autodock tool – Vina (Scripps). The binding residues were analyzed by measuring the atoms within 6 Å of L-Quis. The L-Glu and the (s)-MCPG binding sites within the hinge region were analyzed using Dymdon.

MD simulation and correlation analysis using Amber. The initial coordinates for all the simulations were taken from a 2.20 Å resolution x-ray crystal structure with PDBID 1EWK (19). The AMBER 10 suite of programs (20) was used to carry out all of the simulations in an explicit TIP3P water model (21), using the modified version of the all-atom Cornell et. al. (22) force field and the re-optimized dihedral parameters for the peptide ω-bond. (23) The crystal structure contains only PHE substrate. Ca^{2+} ion was placed at the suggested Ca^{2+}-binding site that is defined by residues D318, D322, and E325. An initially 2 ns simulation was performed using NOE restraint during the equilibration in order to reorient the side chains residues in the Ca^{2+}-binding site, but no restraints were used during the actual simulation. A total of four MD simulations were carried out for 50 ns each on wild type and three mutant mGluRs. The mutations were D318I, D322I, and E325I. First, our structures were minimized to achieve the lowest-energy conformation in each complex. The structures were then equilibrated for 2 ns, starting the MD simulations from the equilibrated structures. During the simulations, an integration time step of 0.002 ps was used to solve Newton's equation of motion. The long-range electrostatic interactions were calculated using Particle Mesh Ewald method (24) and a cutoff of 9.0 Å was applied for non-bonded interactions. All bonds involving hydrogen atoms were restrained using the

SHAKE algorithm (25). The simulations were carried out at a temperature of 300 K and a pressure of 1 bar. A Langevin thermostat was used to regulate the temperature with a collision frequency of 1.0 ps^{-1}. The trajectories were saved every 500 steps (1ps). The trajectories were then analyzed using the ptraj module in Amber 10.

Constructs, site-directed mutagenesis, and expression of mGluR1α variants. The red fluorescent protein, mCherry, was genetically tagged to the C-terminal of mGluR1α by a flexible linker—GGNSGG(18). Point mutations were introduced using a site-directed mutagenesis kit (Strategene). HEK293 cells were seeded and cultured on glass coverslips. MGluR1α and its mutants were transfected into cells utilizing lipofectamine 2000 (Invitrogen). The cells were then incubated for two additional days, so that mGluR1α and its mutants were expressed at sufficient levels for study. Cells were fixed on the coverslips with 4% formaldehyde, and nuclei were stained with DAPI. The expression of mGluR1α and its variants were detected by measuring red fluorescence using confocal microscopy at 587 nm.

Determining the effect of $[Ca^{2+}]_o$ on activation of mGluR1α and its mutants by L-Quis. Measurement of $[Ca^{2+}]_i$ was performed as described (13). In brief, wild type mGluR1α was transiently transfected into the cells and cultured for two additional days. The cells on the coverslips were subsequently loaded using 4 μM Fura-2 AM in 2 mL physiological saline buffer (10 mM HEPES, 140 mM NaCl, 5 mM KCl, 0.55 mM $MgCl_2$, 1 mM $CaCl_2$ and pH 7.4) for 30 min. The coverslips were then mounted in a bathing chamber on the stage of a fluorescence microscope at room temperature. Fura-2 emission signals at 510 nm from single cells excited at 340 or 380 nm were collected utilizing a Leica DM6000

4

fluorescence microscope in real time as the concentration of L-Quis was progressively increased in the presence or absence of $[Ca^{2+}]_o$. The ratio of fluorescence emitted at 510 nm resulting from excitation at 340 or 380 nm was further analyzed to obtain the $[Ca^{2+}]_i$ response as a function of changes in L-Quis. Only the individual cells with mCherry expressed were selected for analysis.

Measurement of $[Ca^{2+}]_i$ responses of mGluR1α to $[Ca^{2+}]_o$ or L-Glu in the presence of 0.5 mM s-MCPG. The methods for measuring $[Ca^{2+}]_i$ responses were as described above. In the presence of (s)-MCPG, the cells were incubated with 0.5 mM (s)-MCPG in a L-Glu-free saline buffer for 30 more minutes after Fura-2 loading. Then, the sensitivity of mGluR1α to $[Ca^{2+}]_o$ or added L-Glu was measured either by increasing the concentration of L-Glu in the presence of 1.8 mM $[Ca^{2+}]_o$, or by increasing $[Ca^{2+}]_o$ in a stepwise manner in the saline buffer with or without 0.5 mM (s)-MCPG. The L-Glu concentrations were recorded at which the $[Ca^{2+}]_i$ responses of mGluR1α were first observed and then were saturated.

Determining the effects of $[Ca^{2+}]_o$ on the potency of Ro 67-4853 on mGluR1α. Fura-2AM was used for monitoring $[Ca^{2+}]_i$ in real time as described above. Ro 67-4853 did not potentiate mGluR1α in the absence of L-Glu (26,27). To obtain the $[Ca^{2+}]_i$ readout, HEK293 cells expressing mGluR1α were pre-incubated with 0.5 mM Ca^{2+} and 5 nM Ro 67-4853 for at least 10 minutes. Cells loaded with Fura-2AM were mounted onto a chamber perfused with saline buffer. By increasing the concentration of Ro 67-4853 stepwise in the presence of 0.5 mM or 1.8 mM $[Ca^{2+}]_o$ $[Ca^{2+}]_i$ was recorded as before by the ratiometric change of fura-2AM in response to changes in $[Ca^{2+}]_i$. The effect of $[Ca^{2+}]_o$ was analyzed by comparing the intracellular Ca^{2+} responses elicited by Ro

67-4853 at two different concentrations of Ca^{2+} in the perfusion buffer. To determine the effect of Ro 67-4853 on the sensitivity of mGluR1α to $[Ca^{2+}]_o$, an additional 30 nM or 300 nM Ro 67-4853 was applied as $[Ca^{2+}]_o$ was increased.

Measurement of $[Ca^{2+}]_i$ responses of mGluR1α to $[Ca^{2+}]_o$ or L-Glu in the presence of CPCCOEt. After the coverslip was mounted in the microscope, the cells were perfused with a saline buffer containing 0, 5 or 40 μM CPCCOEt for more than 10 min. Increasing concentrations of $[Ca^{2+}]_o$ or L-Glu were added to the chamber in the presence of varying concentrations of CPCCOEt, and the $[Ca^{2+}]_i$ response was recorded.

Determining the effects of $[Ca^{2+}]_o$ on $[^3H]$-L-Quis binding to mGluR1α and its mutants. HEK293 cells transiently transfected with wild type mGluR1α or its mutants were maintained in a 5% CO_2 37^oC incubator for an additional 48 hours as before. Cells were then collected in ice cold hypotonic buffer (20 mM HEPES, 100 mM NaCl, 5 mM $MgCl_2$, 5 mM KCl, 0.5 mM EDTA, and 1% protease inhibitors at pH 7.0-7.5). The cell pellet was washed twice more using hypotonic buffer to remove the L-Glu in the cellular debris. The crude membrane protein (100 μg) was mixed with 30 nM $[^3H]$-L-Quis in 100 μL of hypotonic buffer. The nonspecific binding was determined by measuring bound $[^3H]$-L-Quis in the presence of 200 μM L-Glu. To study the effects of $[Ca^{2+}]_o$ on L-Quis binding to mGluR1α, increasing concentrations of $[Ca^{2+}]_o$ were applied. The reaction mixtures were incubated on ice for at least 1 hour, and the membrane-bound $[^3H]$-L-Quis was captured on filter paper using a Brandel cell harvester under vacuum. The filter paper was then transferred to scintillation fluid, and $[^3H]$-L-Quis was detected using a Beckman LS 6500 multi-purpose scintillation counter.

5

RESULTS

Predicted [Ca^{2+}]_o-binding site is adjacent to orthosteric agonist and antagonist binding sites. Using our recently developed computational algorithms, we have identified a novel potential Ca^{2+}-binding site at the hinge region of the ECD of mGluR1α (18). Fig. 1 shows that the predicted Ca^{2+}-binding site is comprised of D318, E325, D322, and the carboxylate side chain of the natural agonist, L-Glu, in the hinge region in the ECD of mGluR1α, adjacent to the reported L-Glu-binding site. D318 is involved in both L-Glu- and Ca^{2+}-binding (18).

Using the crystal structure (1EWK, closed-open form) of the receptor's ECD and Autodock-Vina program, we modeled the binding site for the orthosteric agonist, L-Quis. As shown in Fig. 1B, the docked binding site of the agonist, L-Quis, corresponds well with the L-Glu-binding residues previously suggested by the crystal structure. Our predicted Ca^{2+}-binding site is also adjacent to the L-Quis pocket and interacts with L-Quis similarly to L-Glu (Fig. 1B). In the reported crystal structure of mGluR1 complexed with an orthosteric antagonist, (s)-MCPG (PDBID: 1ISS), (s)-MCPG interacts with Y74, W110, S165, T188, and K409 in lobe one (LB1) and D208, Y236 and D318 in lobe two (LB2) (Fig 1B) (10). It shares with L-Glu most of the residues of the L-Glu-binding pocket (10) and is also adjacent to our predicted Ca^{2+}-binding site.

We next performed Molecular Dynamics simulations to reveal any possible interaction between our predicted [Ca^{2+}]_o-binding site and the orthosteric ligand-binding site. Residues involved in the [Ca^{2+}]_o-binding pocket, such as D318, D322, and E325, have strong correlated motions, as expected given their roles as [Ca^{2+}]_o-binding

ligands. In addition, residues D318 and R323 residing within the same loop as the predicted Ca^{2+}-binding site are also concurrently correlated. As shown in Figure 2, most of the critical L-Glu-binding residues, including W110, S165, T188, D208, Y236, D318 and R323, are well correlated to the [Ca^{2+}]_o-binding site (D318, D322 and E325). However, mutations at the charged residues involved in [Ca^{2+}]_o-binding, such as D318I and E325I, markedly attenuate the correlation of the Ca^{2+}-binding site with the L-Glu binding pocket. The Ca^{2+}-binding site in mutant D318I only correlates with G293 and D208, and mutant D325I only correlates with Y236 and G293. The mutant D322I also exhibits impaired correlation between the [Ca^{2+}]_o-binding site and L-Glu-binding site, but to a lesser degree. As shown in Table 1, D318 in the [Ca^{2+}]_o-binding site still correlates with four residues in the L-Glu-binding pocket (Fig. 2). Similarly, residues that are involved in binding L-Quis and (s)-MCPG also correlate well with residues involved in the predicted [Ca^{2+}]_o-binding site. Results from these analyses and our previous studies on the effect of binding of [Ca^{2+}]_o to its site on L-Glu-mediated activation of mGluR1 lead us to hypothesize that [Ca^{2+}]_o regulates the effects of orthosteric ligands on mGluR1α.

Ca^{2+} enhances sensitivity of activation of mGluR1α by L-Quis by increasing [^{3}H]-L-Quis binding via interaction with the [Ca^{2+}]_o-binding site of the receptor. To test the effect of [Ca^{2+}]_o on the activation of mGluR1α by the orthosteric agonist, L-Quis, we performed a single cell fluorescence imaging assay by measuring changes in [Ca^{2+}]_i using HEK293 cells transiently transfected with mGluR1α and loaded with fura-2. To eliminate any potential effect of trace L-Glu secreted from cells, experiments were conducted using continuous superfusion of cells with an L-Glu-free buffer. Fig. 3A-D show that L-Quis induces

6

intracellular calcium responses mediated by mGluR1 in a similar manner to the activation of the receptor by L-Glu. $[Ca^{2+}]_o$ behaves as a PAM of the L-Quis response and induces a leftward shift in the L-Quis CRC (concentration-response curve) for activation of mGluR1a (Fig. 3A-D). In the absence of $[Ca^{2+}]_o$ (Ca^{2+}-free buffer with less than 2 μM calcium), the EC_{50} for the activation of mGluR1a by L-Quis is 12.8 nM. The addition of 1.8 mM $[Ca^{2+}]_o$ reduces the EC_{50} of L-Quis to 2.8 nM (about 4.6 fold) (Fig. 3D, Table 2). This $[Ca^{2+}]_o$-mediated increase in the potency of L-Quis is similar to the effect of $[Ca^{2+}]_o$ on the activation of mGluR1 by its natural agonist, L-Glu (18).

To test whether this $[Ca^{2+}]_o$-mediated increase in the potency of L-Quis occurs via our predicted $[Ca^{2+}]_o$-binding site in the ECD of the receptor, we then examined three mGluR1 variants with mutations around the $[Ca^{2+}]_o$-binding site adjacent to the orthosteric binding site at the hinge region. The negatively charged side chain of E325 has previously been shown to be important for $[Ca^{2+}]_o$-binding by mGluR1 and not directly involved in L-Glu-binding (18). Removal of the $[Ca^{2+}]_o$-binding ligand residue E325 in the mGuR1 variant E325I reduces potency, increasing the EC_{50} from 12.6 to 20 nM in the absence of $[Ca^{2+}]_o$ (Fig 3D and Table 2). Importantly, this mutation significantly reduces the $[Ca^{2+}]_o$-mediated enhancement in potency for L-Quis from 4.6-fold to 1.6-fold in 1.8 mM $[Ca^{2+}]_o$, although both the potency and efficacy of L-Quis-mediated activation of the E325I mutant are still enhanced relative to WT mGluR1 (Fig 3A-D). As L-Glu could potentially serve as a ligand for binding of Ca^{2+} to its pocket, L-Glu- or L-Quis-binding could rescue the mutated Ca^{2+}-binding pocket, thus enhancing the Ca^{2+} sensitivity of the mutant. On the other hand, mutant D322I exhibits WT-like behavior in its

response to L-Quis both in the absence and presence of $[Ca^{2+}]_o$ (Fig. 3A-D, Table 2), consistent with D322 contributing to $[Ca^{2+}]_o$-binding to a lesser degree, with only its main chain oxygen serving as a ligand atom. We also observed WT-like modulation of the L-Glu response of D332I by Ca^{2+} (18). These $[Ca^{2+}]_i$ imaging data suggest that $[Ca^{2+}]_o$ plays a key role in modulating the activation of mGluR1α by L-Quis, possibly via interaction of $[Ca^{2+}]_o$ at the predicted $[Ca^{2+}]_o$-binding site.

We utilized a direct binding assay with radioactive L-Quis ($[^3H]$-L-Quis) to assess the impact of $[Ca^{2+}]_o$ on the binding of $[^3H]$-L-Quis to mGluR1α or its variants with mutations at the predicted $[Ca^{2+}]_o$-binding ligand residues in the absence or presence of $[Ca^{2+}]_o$. L-Quis binds to the wild type receptor expressed in HEK293 with a K_D in the range of 30 nM. L-Glu reduces L-Quis binding by competing for the similar orthosteric binding pocket (Figs. 1B, 4B Insert). $[Ca^{2+}]_o$ significantly enhances L-Quis-binding to the wild type receptor with an EC_{50} in the range of 0.3 mM (Fig 3E, Table 2). Variant E325I, with removal of negative charge on the key $[Ca^{2+}]_o$-binding residue E325, abolishes L-Quis binding, and this effect is not influenced by the addition of L-Glu or $[Ca^{2+}]_o$ ($K_d > 20$ mM) (Table 2). On the other hand, variant D322I retains the binding properties of the wild type receptor for L-Quis suggesting its less essential role in L-Quis binding (Fig 3E), which is consistent with its role in activation of the $[Ca^{2+}]_i$ responses described earlier. Taken together, both the studies of $[Ca^{2+}]_i$ responses and L-Quis-binding suggest that $[Ca^{2+}]_o$ enhances the activation of mGluR1 by L-Quis by directly modulating binding of L-Quis to mGluR1 through an interaction with predicted $[Ca^{2+}]_o$-binding site 1 in the hinge region.

(s)-MCPG reduces the sensitivity of mGluR1α to L-Glu and [Ca²⁺]ₒ. The effects

of $[Ca^{2+}]_o$ on various mGluR1 ligands acting by different mechanisms on mGluR1 were evaluated using L-Glu as the orthosteric agonist, since it is the physiological activator of the receptor *in vivo*. As shown in Figure 4, (s)-MCPG induces a concentration-dependent decrease in the L-Glu-evoked $[Ca^{2+}]_i$ response (Fig. 4A). A concentration of 0.5 mM (s)-MCPG elicits a parallel rightward shift in the L-Glu CRC, and increases the EC_{50} for L-Glu from 1.7 to 3.7 μM. This is consistent with the known action of MCPG as a competitive antagonist at the orthosteric L-Glu binding site.

Interestingly, Fig 4A shows that MCPG also induces a concentration-dependent inhibition of the 5 mM $[Ca^{2+}]_o$-induced $[Ca^{2+}]_i$ response, even in the absence of added L-Glu. Unlike the effect of MCPG on the response to L-Glu, MCPG does not completely block the response to $[Ca^{2+}]_o$. This is consistent with the hypothesis that MCPG inhibits the response to $[Ca^{2+}]_o$ by acting at a site distinct from the one that allosterically regulates the response to $[Ca^{2+}]_o$. MCPG also induces a rightward shift in the $[Ca^{2+}]_o$ CRC. The EC_{50} for $[Ca^{2+}]_o$ increases by ~1.7 fold (from 3.5 to 6.0 mM at 0 and 0.5 mM MCPG, respectively) (Fig. 4C, Table 3). The maximal response to $[Ca^{2+}]_o$ was not affected by 0.5 mM MCPG. However, as noted above, higher concentrations of MCPG could not fully block the maximal effect of 5 mM $[Ca^{2+}]_o$.

NAM CPCCOEt noncompetitively inhibits both L-Glu-induced and $[Ca^{2+}]_o$-induced activation of mGluR1α. CPCCOEt is known as a selective, non-competitive negative allosteric modulator (NAM) of mGluR1 that binds to residues T815 and A818 in the 7th TMD of the receptor (28) (Fig. 1). As shown in Fig. 5A, the L-Glu-triggered $[Ca^{2+}]_i$ response is significantly depressed in the presence of 5 and 40 μM CPCCOEt. In the presence of 40 μM

CPCCOEt, the maximal response decreases to only about half of the control level, while the EC_{50} value increases from 1.7 to 10.1 μM (Fig. 5A, Table 4). To determine the effects of CPCCOEt on the activation of mGluR1α by $[Ca^{2+}]_o$, we next examined the effect of CPCCOEt on $[Ca^{2+}]_o$-induced $[Ca^{2+}]_i$ responses. Fig. 5B reveals that CPCCOEt significantly inhibits the $[Ca^{2+}]_o$ sensitivity of mGluR1α. In the presence of 5 μM CPCCOEt, the EC_{50} of mGluR1α for $[Ca^{2+}]_o$ was increased from 3.5 to 14.7 mM. A concentration of 40 μM CPCCOEt produces an even higher EC_{50} value of 28.7 mM (Fig. 5B, Table 4). The maximal response is also significantly decreased by 40 μM CPCCOEt, although the maximal response with 5 μM CPCCOEt is still comparable. This indicates that 30 mM $[Ca^{2+}]_o$ cannot completely reverse the antagonism induced by CPCCOEt, and thus the inhibitory effects of CPCCOEt on the response of mGluR1α to $[Ca^{2+}]_o$ appears to be non-competitive (Fig. 5B, Table 4).

The mGluR1α PAM Ro 67-4853 potentiates activation of mGluR1 by $[Ca^{2+}]_o$. The finding that CPCCOEt inhibits activation of mGluR1 by $[Ca^{2+}]_o$ suggests that the CPCCOEt site, in the transmembrane-spanning domain of mGluR1, and the $[Ca^{2+}]_o$-binding site, in the ECD of the receptor, interact in a manner similar to the interactions between the orthosteric L-Glu binding site and the allosteric CPCCOEt site. We performed analogous experiments to determine whether the mGluR1 PAM, Ro 67-4853, which binds to the extracellular loops of the TMDs of mGluR1α, (2,29) (Fig. 1B), can also potentiate responses to $[Ca^{2+}]_o$. Fig 6A shows that L-Glu-induced activation of WT mGluR1α is enhanced by the addition of 10 or 100 nM Ro 67-4853 using single cell $[Ca^{2+}]_i$ imaging. We then examined the effects of Ro 67-4853 on the $[Ca^{2+}]_o$ sensitivity of wild type mGluR1α in the

8

absence of L-Glu. Fig. 6B shows that both 30 and 300 nM Ro 67-4853 enhanced the $[Ca^{2+}]_i$ response induced by $[Ca^{2+}]_o$, reducing the EC_{50} values for $[Ca^{2+}]_o$ from 3.5 mM to 2.1 and 0.7 mM, respectively. As with the effect of Ro 67-4853 on the response to L-Glu, the maximal response to $[Ca^{2+}]_o$ is not changed by Ro 67-4853 (Fig. 6B and Table 5).

To further evaluate the effect of Ro 67-4853 on mGluR1α, HEK293 cells transiently expressing mGluR1α were pre-incubated with 0.5 mM Ca^{2+} and 5 nM Ro 67-4853 for up to 10 minutes, and then the responses to multiple concentrations of Ro 67-4853 were tested. In the presence of 0.5 mM $[Ca^{2+}]_o$, Ro 67-4853 enhances L-Glu-induced mGluR1α activity in a concentration-dependent manner. Increasing $[Ca^{2+}]_o$ to 1.8 mM significantly increases the potency of low dosage of Ro 67-4853 for mGluR1α ($P < 0.05$) (Fig. 6C). At the same time, the EC_{50} value decreases from 20.7 to 10.0 nM (Fig. 6C, Table 5). Interestingly, $[Ca^{2+}]_i$ oscillations are observed when the cells are treated with Ro 67-4853 (data not shown). Similar to the Ca^{2+}-sensing receptor, three different patterns of response are noted (30). Most of the cells display a transient spike in $[Ca^{2+}]_i$. Some cells start oscillating after the first peak, while others have a transient peak and oscillations first appear a few minutes later. By analyzing the number of cells oscillating out of the total number of responsive cells, 1.8 mM $[Ca^{2+}]_o$ significantly increases the number of oscillatory cells compared to the cells in 0.5 mM $[Ca^{2+}]_o$. The starting point of oscillation is also shifted leftward (Data not shown). This suggests that $[Ca^{2+}]_o$ enhances the potency of Ro 67-4853 in activating mGluR1α.

To understand whether this modulation by $[Ca^{2+}]_o$ of the action of this allosteric modulator acting via the TMDs is indeed a result of $[Ca^{2+}]_o$-binding to the predicted $[Ca^{2+}]_o$-binding site in the ECD (e.g., Fig. 1), we then performed studies using an mGluR variant with a key $[Ca^{2+}]_o$-binding ligand residue mutated, E325I. Fig. 1B shows that E325 is not directly involved in L-Glu-binding, and variant E325I is able to sense L-Glu in a manner similar to WT (18). Fig. 7A shows that addition of 30 μM L-Glu enhances the responsiveness of E325I to Ro 67-4853. Of note, Fig 7B shows that E325I responds to 10 μM Ro 67-4853 in the absence of L-Glu in $[Ca^{2+}]_o$-free saline. Increasing $[Ca^{2+}]_o$ from 0.5 to 1.8 mM does not affect the sensitivity of E325I to Ro 67-4853, but elevating $[Ca^{2+}]_o$ increases the responses of WT mGluR1α to 300 nM Ro 67-4853 (Fig. 7B). This suggests that mutating the Ca^{2+}-binding site (E325I) eliminates the effect of Ca^{2+} on Ro 67-4853, but not on WT mGluR1α. To determine if the receptors were saturated by Ro 67-4853, higher concentrations of the PAM were applied to both WT mGluR1 and E325I. As shown in Fig. 7B, higher concentrations of Ro 67-4853 increase the responses of both WT mGluR1 and E325I. This result suggests that $[Ca^{2+}]_o$-binding at its predicted site in the hinge region is essential for the positive allosteric action of this modulator.

DISCUSSION

In this paper, we have demonstrated that $[Ca^{2+}]_o$ has significant modulating effects on the actions of various orthosteric and allosteric ligands on mGuR1a, as assessed using a functional readout (i.e., $[Ca^{2+}]_i$ responses) in receptor-transfected HEK293 cells. $[Ca^{2+}]_o$ exerted several different effects on the compounds studied here, including the orthosteric agonist, L-Quis, the orthosteric antagonist, MCPG, and allosteric modulators, e.g., the PAM Ro 67-4853 and the NAM CPCCOEt.

As shown in Fig. 1, the predicted $[Ca^{2+}]_o$-binding site partially overlaps the predicted orthosteric binding site for the

9

agonist, L-Quis, and the antagonist, MCPG. We have previously reported the effects of $[Ca^{2+}]_o$ on $[L-Glu]_o$-induced activation of the receptor. Consistent with this, we have shown here that activation of mGluR1α by L-Quis was enhanced by $[Ca^{2+}]_o$ in a similar manner. Through binding to the Ca^{2+}-binding site on the ECD of mGluR1, $[Ca^{2+}]_o$ was capable of inducing the hydrolysis of PIP_2, thus increasing IP_3 and Ca^{2+} release from the ER (18). As reported, $[Ca^{2+}]_o$ was shown to synergistically activate mGluR1α with L-Glu (18). However, activation of GPCRs is also known to induce Ca^{2+} influx through store-operated Ca^{2+} entry channels (31,32). By utilizing Gd^{3+}, an inhibitor of these Ca^{2+} channels, we noted that mGluR1a still could induce an increase in $[Ca^{2+}]_i$ (18). But comparing this increase to the $[Ca^{2+}]_o$-induced concentration response curve, the Gd^{3+} response after the transient increase in $[Ca^{2+}]_i$ returned the curve back to the baseline (33). This suggests that Ca^{2+} release from the ER predominantly induces a transient peak, while Ca^{2+} influx elevates the plateau portion of the response. We also further demonstrated that increasing $[Ca^{2+}]_o$ enhanced L-Quis binding to HEK293 cells over-expressing mGluR1α, while the mutant E325I abolished this effect of $[Ca^{2+}]_o$ on the activation of mGluR1 (Fig 3). Moreover, a clear difference in L-Quis and L-Glu binding was observed in the presence of physiological levels of $[Ca^{2+}]_o$. $[Ca^{2+}]_o$ in the synaptic cleft changes at the range from 0.8 to 1.5 mM (34), and mGluR1α is known to respond the $[Ca^{2+}]_o$ change between 0.5 and 1.5 mM (18). Using purified ECD of mGluR1α, Jingami et al. reported that $[Ca^{2+}]_o$ enhances the increase in Trp fluorescence induced by L-Quis and L-Glu (15), although $[Ca^{2+}]_o$ was reported to have no effect on L-Quis binding (35). Nash et al. also observed that $[Ca^{2+}]_o$ produces a higher plateau $[Ca^{2+}]_i$ response and greater IP_3 accumulation in CHO cells mediated by

mGluR1α (36), although the transient increase in $[Ca^{2+}]_i$ was not affected. Thus, our observation that $[Ca^{2+}]_o$ enhanced both L-Quis-induced $[Ca^{2+}]_i$ responses and L-Quis binding to the receptor has a physiological implication similar to the modulation by $[Ca^{2+}]_o$ of the action of L-Glu on mGluR1α. Fig 1 shows that the predicted $[Ca^{2+}]_o$-binding site is located adjacent to the (s)-MCPG binding pocket in mGluR1 in the X-ray structure (PDBID: 1ISS), which is in the hinge region of the ECD and occupies most of the residues involved in L-Glu-binding (10). We tested the effects of gradually increasing concentrations of the orthosteric antagonist, (s)-MCPG, on $[Ca^{2+}]_o$-induced signaling by mGluR1α. As shown in Fig 4, (s)-MCPG reduced the $[Ca^{2+}]_o$ sensitivity of mGluR1α (Fig. 4A and C). Here we have shown that increases in the concentrations of either $[Ca^{2+}]_o$ or L-Glu overcame the inhibition induced by (s)-MCPG (Fig. 4). It is interesting to note that (s)-MCPG could not completely block the $[Ca^{2+}]_o$ sensitivity of mGluR1 (Fig. 4C). $[Ca^{2+}]_o$-induced responses mediated by mGluR1α were found to be only partially antagonized by (s)-MCPG (4). (s)-MCPG, was shown to have the capacity to completely inhibit L-Glu-potentiated Ca^{2+}-activated Cl^- currents in *Xenopus laevis* oocytes transiently expressing mGluR1 (4). These data support our hypothesis that $[Ca^{2+}]_o$ modulates the effects of orthosteric ligands on mGluR.

The observed $[Ca^{2+}]_o$-modulated orthosteric effect is likely dependent on communication of the predicted $[Ca^{2+}]_o$-binding site with the adjacent binding site for orthosteric agonists and antagonists. We first showed that the L-Quis binding pocket predicted here using AutoDock-Vina overlaps extensively with the L-Glu-binding pocket in the reported crystal structure (Table 6). The side-chain of D318 is involved in both $[Ca^{2+}]_o$- and agonist-

10

binding. In our earlier study, the mutation D318I was shown to abrogate both the sensitivity to $[Ca^{2+}]_o$ and responsiveness to L-Glu (18). In this study, it also completely eliminated L-Quis-mediated activation of mGluR1 (Fig. 3E). This finding is supported by a previous report that the mutants T188A, D208A, Y236A and D318A abolished the sensitivity of the receptor to both L-Quis and L-Glu, while the mutants R78E and R78L exhibited clearly impaired L-Quis binding (8,9). The key residue E325 is involved in $[Ca^{2+}]_o$-binding, and the mutant, E325I, indeed significantly impaired both the $[Ca^{2+}]_o$ and L-Glu sensitivity of the receptor (Fig. 3). On the other hand, variant D322I produced less reduction of the modulatory effects of $[Ca^{2+}]_o$ on both L-Quis and L-Glu agonist action and is consistent with its lesser role in $[Ca^{2+}]_o$-binding with a contribution of only a main chain ligand atom (Fig 1).

Our observed effect of $[Ca^{2+}]_o$ on responses to orthosteric agonists and antagonists of mGluR1 is consistent with Molecular Dynamics Simulation studies performed here on the correlated motions of the hinge region in the ECD of mGluR (Fig 2, Table 1). We have observed a strong correlation among residues in the predicted $[Ca^{2+}]_o$-binding site and residues involved in the orthosteric binding sites shared by L-Glu, L-Quis and MGPG. Interestingly, mutation of the $[Ca^{2+}]_o$-binding site largely removed this correlation. Fig. 1A shows that the predicted $[Ca^{2+}]_o$-binding site at the hinge region is conserved in the group I mGluRs, e.g., mGluR1 and mGluR5 (18), calcium-sensing receptor and T1R3, a taste receptor for $[Ca^{2+}]_o$, (37). In our previous study, $[Ca^{2+}]_o$ exhibits synergy with L-Glu in activating mGluR1α (18). We have further demonstrated here the effect of $[Ca^{2+}]_o$ in modulating orthosteric ligands that act on mGluR via communication at the hinge region of the ECD. We and others have also shown that binding of L-Phe and other amino acids to a site in the hinge region of the CaSR likely communicates with the predicted $[Ca^{2+}]_o$-binding site at the hinge region to increase the sensitivity of the receptor to $[Ca^{2+}]_o$ (12,13,38,39). In recent years, increasing numbers of family C GPCRs have been found to exhibit synergistic modulation of the primary orthosteric agonist by allosteric modulators. Sweet enhancers binding to the hinge region of the human taste receptor are known to stabilize the active form of the receptor, thus leading to altered perception of sweet taste, while IMP and L-Glu also synergistically activate the umami taste receptor (40,41). It is also interesting to note that an allosteric ligand suggested to act at the ECD domain of mGluR is located at the hinge region (42,43). Thus, our work has strong implications for the role of the hinge region of the ECD in modulating action of small molecule ligands on family C GPCRs.

As for allosteric modulators targeting the TMDs, the binding sites of positive and negative modulators of mGluR1α are distinct (44). These allosteric modulators effectively modulate receptor activation by L-Glu, but little is known about the effects of the endogenous mineral ion, Ca^{2+}, on these modulators. In this study, the effects of $[Ca^{2+}]_o$ on CPCCOEt (NAM) and Ro 67-4853 (PAM) were further assessed.

The non-competitive NAM, CPCCOEt, is known to inhibit the L-Glu response by binding to T815 and A818 on the 7th transmembrane helix) (45,46). Our data shown in Fig. 5 support the contention that CPCCOEt, acting as a non-competitive inhibitor, also can diminish the $[Ca^{2+}]_i$ response of mGluR1α. Interestingly, increasing $[Ca^{2+}]_o$ restored the $[Ca^{2+}]_o$ sensitivity of the receptor. CPCCOEt not only inhibits proliferation of melanoma cells, but also reverses morphine tolerance (47,48). Thus, the findings in this study indicate that

11

a novel drug targeting the $[Ca^{2+}]_o$-binding site in mGluR1 has the potential to tune the therapeutic effect of CPCCOEt on melanoma or addiction. V757 in the TMD was revealed to be critical to the activation of mGluR1 by the PAMs (27,44). By analyzing the $[Ca^{2+}]_i$ transients and oscillations observed here, $[Ca^{2+}]_o$ not only reduced the concentration of Ro 67-4853 required to initiate $[Ca^{2+}]_i$ oscillations, but also decreased the EC_{50} value and increased the maximal responses of HEK293 cells expressing mGluR1 (Fig. 6 and Table 5). In the presence of Ro 67-4853, the $[Ca^{2+}]_o$ sensitivity of mGluR1α was also enhanced, indicating an allosteric interaction between the $[Ca^{2+}]_o$-binding site and the site for Ro 67-4583. Interestingly, Ro 67-4853 only enhanced activation of mGluR1α by physiological $[Ca^{2+}]_o$ concentrations, while further increases in $[Ca^{2+}]_o$ abolished the Ro 67-4853 effect (Fig. 7B) ($p < 0.01$). This indicates that a change in $[Ca^{2+}]_o$ within the physiological range could serve as a PAM, similar to Ro 67-4853, and suggests that $[Ca^{2+}]_o$-induced enhancement of the potency of Ro 67-4853 may activate mGluR1 via the TMDs, and that the activation of the TMDs could enhance the sensitivity of the receptor to agonist. Since site-directed mutagenesis suggests that Ro 67-4853 along with the other PAMs, Ro 01-6128, and Ro 67-7476, likely share the same binding pocket involving V757. $[Ca^{2+}]_o$ could potentially enhance the potencies of other members of the Ro and VU series.

The observed modulation of the effects of PAM and NAM by $[Ca^{2+}]_o$ can be explained by the integrated action of the ECD domain with the TMDs of the receptor. This is supported by our studies using a mutation of a key $[Ca^{2+}]_o$-binding ligand residue, E325I, at the predicted $[Ca^{2+}]_o$-binding site adjacent to the L-Glu-binding site. Variant E325I markedly reduces the modulation of the action of Ro67-4853 by

$[Ca^{2+}]_o$ (Fig. 7). PAMs binding to the TMDs have been shown to enhance L-Quis binding to mGluR1α (27). It is possible that the incomplete reduction in the inhibitory effect of MCPG by $[Ca^{2+}]_o$ is due to an additional synergistic effect involving the TMD region of the receptor. By tagging the FRET pair YFP/CFP to the two intracellular loops 2 (i2) of the dimeric mGluR1α, Muto et al. observed that the re-arrangement of the TMD induced by L-Glu was reversed by (s)-MCPG (49). Such an integrated effect of the TMD with the ECD region is further supported by studies of mGluRs with deletions of the VFT. It was found that PAMs not only potentiate the action of agonists on the full-length receptors, but sometimes can display strong agonist activity on VFT truncated receptors (50,51). The VFTs of the ECDs are not only responsible for agonist-induced activation, but also prevent PAMs from activating the full-length receptor (50,51). Taken together, our study reveals that $[Ca^{2+}]_o$-binding at the hinge region is likely to be responsible for its capacity to modulate action of other allosteric modulators. $[Ca^{2+}]_o$ at physiological levels (1.8 mM) enhanced the potency of Ro 67-4853 in modulating mGluR1α, while increasing $[Ca^{2+}]_o$ diminished the inhibitory effects of CPCCOEt (Figs. 5-7, Tables 4-5). Over the past decade, many new PAMs and NAMs for various receptors have been developed, and the potential exists for developing allosteric modulators with greater subtype specificity than is possible for orthosteric agonists (52). The co-activation induced by endogenous agonists and PAMs binding to the receptors' hinge regions could be a common feature of family C GPCRs. These data provide further insight into the modulation of mGluR1α by $[Ca^{2+}]_o$ and suggest that $[Ca^{2+}]_o$ has the potential to modulate the profile of a variety of agents

12

acting on mGluR1α, including agonists, antagonists and allosteric modulators.

In conclusion, we investigated the effects of $[Ca^{2+}]_o$ on the modulation of mGluR1α by orthosteric agonists and an orthosteric antagonist, as well as by a PAM and NAM, and found that $[Ca^{2+}]_o$ enhances the actions of agonists and PAMs, but attenuates the actions of antagonists and NAMs. These findings provide new insights into the targeting of mGluR1α by different classes of ligands. In addition to the specific relevance of these findings for understanding the nature of allosteric modulation of mGluR1α, they may also have general relevance for understanding the modulation of Family C GPCRs by extracellular ions such as Ca^{2+}.

ACKNOLEDGEMENTS

REFERENCES

1. Neyman, S., and Manahan-Vaughan, D. (2008) *The European journal of neuroscience* **27**, 1345-1352
2. Lavreysen, H., Janssen, C., Bischoff, F., Langlois, X., Leysen, J. E., and Lesage, A. S. (2003) *Mol Pharmacol* **63**, 1082-1093
3. Lindsley, C. W., Wisnoski, D. D., Leister, W. H., O'Brien J, A., Lemaire, W., Williams, D. L., Jr., Burno, M., Sur, C., Kinney, G. G., Pettibone, D. J., Tiller, P. R., Smith, S., Duggan, M. E., Hartman, G. D., Conn, P. J., and Huff, J. R. (2004) *J Med Chem* **47**, 5825-5828
4. Kubo, Y., Miyashita, T., and Murata, Y. (1998) *Science* **279**, 1722-1725
5. Whang, P. G., O'Hara, B. J., Ratliff, J., Sharan, A., Brown, Z., and Vaccaro, A. R. (2008) *Orthopedics* **31**
6. Yuan, K., Jing, G., Chen, J., Liu, H., Zhang, K., Li, Y., Wu, H., McDonald, J. M., and Chen, Y. (2011) *J Biol Chem* **286**, 24776-24784
7. Chen, Y., Zhou, Y., Lin, X., Wong, H. C., Xu, Q., Jiang, J., Wang, S., Lurtz, M. M., Louis, C. F., Veenstra, R. D., and Yang, J. J. (2011) *Biochem J* **435**, 711-722
8. Levant, J. A., Walsh, J. H., and Isenberg, J. I. (1973) *N Engl J Med* **289**, 555-558
9. Sato, T., Shimada, Y., Nagasawa, N., Nakanishi, S., and Jingami, H. (2003) *J Biol Chem* **278**, 4314-4321
10. Tsuchiya, D., Kunishima, N., Kamiya, N., Jingami, H., and Morikawa, K. (2002) *Proc Natl Acad Sci U S A* **99**, 2660-2665
11. Nagar, B., Overduin, M., Ikura, M., and Rini, J. M. (1996) *Nature* **380**, 360-364
12. Huang, Y., Zhou, Y., Castiblanco, A., Yang, W., Brown, E. M., and Yang, J. J. (2009) *Biochemistry* **48**, 388-398
13. Huang, Y., Zhou, Y., Yang, W., Butters, R., Lee, H. W., Li, S., Castiblanco, A., Brown, E. M., and Yang, J. J. (2007) *J Biol Chem* **282**, 19000-19010
14. Tabata, T., Aiba, A., and Kano, M. (2002) *Mol Cell Neurosci* **20**, 56-68
15. Suzuki, Y., Moriyoshi, E., Tsuchiya, D., and Jingami, H. (2004) *J Biol Chem* **279**, 35526-35534
16. Wang, X., Kirberger, M., Qiu, F., Chen, G., and Yang, J. J. (2009) *Proteins* **75**, 787-798

17. Wang, X., Zhao, K., Kirberger, M., Wong, H., Chen, G., and Yang, J. J. (2010) *Protein science : a publication of the Protein Society* **19**, 1180-1190

18. Jiang, Y., Huang, Y., Wong, H. C., Zhou, Y., Wang, X., Yang, J., Hall, R. A., Brown, E. M., and Yang, J. J. (2010) *J Biol Chem* **285**, 33463-33474

19. Kunishima, N., Shimada, Y., Tsuji, Y., Sato, T., Yamamoto, M., Kumasaka, T., Nakanishi, S., Jingami, H., and Morikawa, K. (2000) *Nature* **407**, 971-977

20. Case, D. A., Darden, T. A., Cheatham, I., T. E. ; , Simmerling, C. L., Wang, J., Duke, R. E., Luo, R., Crowley, M., Walker, R. C., Zhang, W., Merz, K. M., Wang, B., Hayik, S., Roitberg, A., Seabra, G., Kolossváry, I., Wong, K. F., Paesani, F., Vanicek, J., Wu, X., Brozell, S. R., Steinbrecher, T., Gohlke, H., Yang, L., Tan, C., Mongan, J., Hornak, V., Cui, G., Mathews, D. H., Seetin, M. G., Sagui, C., Babin, V., and Kollman, P. A. (2008)

21. Jorgensen, W. L., Chandrasekhar, J., Madura, J. D., Impey, R. W., and Klein, M. L. (1983) *J. Chem. Phys.* **79**, 926-935

22. Cornell, W. D., Cieplak, P., Christopher, I. B., Gould, I. R., Merz, J. K. M., Ferguson, D. M., Spellmeyer, D. C., Fox, T., Caldwell, J. W., and Kollman, P. A. (1995) *J. Am. Chem. Soc.* **117**, 5179-5197

23. Urmi, D., and Hamelberg, D. (2009) *J. Phys. Chem.* **113**, 16590-16595

24. Darden, T., York, D., and Pedersen, L. (1993) *J. Chem. Phys.* **98**, 10089-10092

25. Ryckaert, J. P., Ciccotti, G., and Berendsen, H. J. C. (1977) *J. Comput. Phys.* **23**, 327-341

26. Hepler, R. W., Grimm, K. M., Nahas, D. D., Breese, R., Dodson, E. C., Acton, P., Keller, P. M., Yeager, M., Wang, H., Shughrue, P., Kinney, G., and Joyce, J. G. (2006) *Biochemistry* **45**, 15157-15167

27. Nemeth, E. F., Steffey, M. E., Hammerland, L. G., Hung, B. C., Van Wagenen, B. C., DelMar, E. G., and Balandrin, M. F. (1998) *Proc Natl Acad Sci U S A* **95**, 4040-4045

28. Harrington, P. E., and Fotsch, C. (2007) *Curr Med Chem* **14**, 3027-3034

29. Litschig, S., Gasparini, F., Rueegg, D., Stoehr, N., Flor, P. J., Vranesic, I., Prezeau, L., Pin, J. P., Thomsen, C., and Kuhn, R. (1999) *Mol Pharmacol* **55**, 453-461

30. Huang, Y., Zhou, Y., Wong, H. C., Castiblanco, A., Chen, Y., Brown, E. M., and Yang, J. J. (2010) *The Journal of biological chemistry* **285**, 35919-35931

31. Putney, J. W., Jr. (1986) *Cell calcium* **7**, 1-12

32. Parekh, A. B., and Putney, J. W., Jr. (2005) *Physiological reviews* **85**, 757-810

33. Abe, H., Tateyama, M., and Kubo, Y. (2003) *FEBS Lett* **545**, 233-238

34. Vassilev, P. M., Mitchel, J., Vassilev, M., Kanazirska, M., and Brown, E. M. (1997) *Biophysical journal* **72**, 2103-2116

35. Selkirk, J. V., Price, G. W., Nahorski, S. R., and Challiss, R. A. (2001) *Neuropharmacology* **40**, 645-656

36. Nash, M. S., Saunders, R., Young, K. W., Challiss, R. A., and Nahorski, S. R. (2001) *J Biol Chem* **276**, 19286-19293

37. Dorr, P., Westby, M., Dobbs, S., Griffin, P., Irvine, B., Macartney, M., Mori, J., Rickett, G., Smith-Burchnell, C., Napier, C., Webster, R., Armour, D., Price, D., Stammen, B., Wood, A., and Perros, M. (2005) *Antimicrob Agents Chemother* **49**, 4721-4732

38. Conigrave, A. D., Mun, H. C., and Lok, H. C. (2007) *The Journal of nutrition* **137**, 1524S-1527S; discussion 1548S

39. Zhang, Z., Qiu, W., Quinn, S. J., Conigrave, A. D., Brown, E. M., and Bai, M. (2002) *J Biol Chem* **277**, 33727-33735

40.   Zhang, F., Klebansky, B., Fine, R. M., Liu, H., Xu, H., Servant, G., Zoller, M., Tachdjian, C., and Li, X. (2010) *Proc Natl Acad Sci U S A* **107**, 4752-4757

41.   Zhang, F., Klebansky, B., Fine, R. M., Xu, H., Pronin, A., Liu, H., Tachdjian, C., and Li, X. (2008) *Proc Natl Acad Sci U S A* **105**, 20930-20934

42.   Acher, F. C., Selvam, C., Pin, J. P., Goudet, C., and Bertrand, H. O. (2011) *Neuropharmacology* **60**, 102-107

43.   Ogawa, H., Qiu, Y., Philo, J. S., Arakawa, T., Ogata, C. M., and Misono, K. S. (2010) *Protein science : a publication of the Protein Society* **19**, 544-557

44.   Hemstapat, K., de Paulis, T., Chen, Y., Brady, A. E., Grover, V. K., Alagille, D., Tamagnan, G. D., and Conn, P. J. (2006) *Mol Pharmacol* **70**, 616-626

45.   Rodriguez, A. L., Nong, Y., Sekaran, N. K., Alagille, D., Tamagnan, G. D., and Conn, P. J. (2005) *Mol Pharmacol* **68**, 1793-1802

46.   Brauner-Osborne, H., Jensen, A. A., and Krogsgaard-Larsen, P. (1999) *Neuroreport* **10**, 3923-3925

47.   Haas, H. S., Pfragner, R., Siegl, V., Ingolic, E., Heintz, E., Schraml, E., and Schauenstein, K. (2007) *Oncol Rep* **17**, 1399-1404

48.   Smith, F. L., Smith, P. A., Dewey, W. L., and Javed, R. R. (2004) *Eur J Pharmacol* **492**, 137-142

49.   Tateyama, M., Abe, H., Nakata, H., Saito, O., and Kubo, Y. (2004) *Nat Struct Mol Biol* **11**, 637-642

50.   El Moustaine, D., Granier, S., Doumazane, E., Scholler, P., Rahmeh, R., Bron, P., Mouillac, B., Baneres, J. L., Rondard, P., and Pin, J. P. (2012) *Proceedings of the National Academy of Sciences of the United States of America* **109**, 16342-16347

51.   Goudet, C., Gaven, F., Kniazeff, J., Vol, C., Liu, J., Cohen-Gonsaud, M., Acher, F., Prezeau, L., and Pin, J. P. (2004) *Proceedings of the National Academy of Sciences of the United States of America* **101**, 378-383

52.   Wang, L., Martin, B., Brenneman, R., Luttrell, L. M., and Maudsley, S. (2009) *J Pharmacol Exp Ther* **331**, 340-348

FOOTNOTES

The abbreviations used are: GPCRs, G protein-coupled receptors; ECD, extracellular domain; mGluR, metabotropic glutamate receptor; PLC, phospholipase; IP_3, inositol triphosphate; CRC, concentration-response curve; PAM, positive allosteric modulator; NAM, negative allosteric modulator; L-Quisqualate, (L)-(+)-α-Amino-3,5-dioxo-1,2,4-oxadiazolidine-2-propanoic acid; (s)-MCPG, (s)-α-Methyl-4-carboxyphenylglycine; CPCCOEt, 7-(Hydroxyimino) cyclopropa[*b*]chromen-1a-carboxylate ethyl ester; Ro 67-4853, (9*H*-Xanthen-9-ylcarbonyl)-carbamic acid butyl ester.

FIGURE LEGENDS

FIGURE 1**. Schematic view of the binding sites for $[Ca^{2+}]_o$, L-Glu, L-Quis and (s)-MCPG in the mGluR1α ECD.** (A) The $[Ca^{2+}]_o$-binding site is highly conserved in group I mGluRs and T1R3. In contrast, while sequence alignment suggests that the $[Ca^{2+}]_o$ binding site is highly conserved in group I mGluRs, it is not conserved in other members of the subfamily. (B) L-Glu,

L-Quis and (s)-MCPG binding pockets (purple diamond), and scheme of binding sites for various classes of ligands acting on mGluR1α. Similar to the L-Glu binding pocket, Y74, R78, S165, T188, Y236, D318, and K409 form the L-Quis binding pocket. Similar residues, Y74, W110, S165, T188, Y236, D318 and K409, that contribute to the L-Glu binding pocket are also involved in binding of (s)-MCPG. L-Glu, L-Quis and (s)-MCPG wedge into a location adjacent to the $[Ca^{2+}]_o$-binding site in the ECD and maintain the structure of the receptor in its active and resting forms, respectively. The residues with more than one dotted lines indicate those that have more than one oxygen atom contributing to ligand binding. Most of the positive (orange triangle) and negative (cyan pentagon) allosteric modulators have been discovered to bind to TMDs but don't share the same binding site.

FIGURE 2. **Correlation maps of WT mGluR1α and D318I, D322I, and E325I.** The predicted $[Ca^{2+}]_o$ binding site is well correlated to the L-Glu-binding pocket. Mutations of the $[Ca^{2+}]_o$-binding site impair the correlation to L-Glu binding pocket. The $[Ca^{2+}]_o$-binding site corresponding to the x-axis is highlighted by rectangle.

FIGURE 3. **Extracellular Ca^{2+} enhances L-Quis activation of mGluR1α by binding to the predicted $[Ca^{2+}]_o$-binding site.** (A-C) Addition of 1.8 mM $[Ca^{2+}]_o$ (solid dot) increases the L-Quis-induced $[Ca^{2+}]_i$ responses mediated by activation of mGluR1α. The response with 0 mM $[Ca^{2+}]_o$ is indicated by the empty circles. In the presence of 1.8 mM $[Ca^{2+}]_o$, the L-Quis sensitivity of D322I was increased. 1.8 mM $[Ca^{2+}]_o$ also enhanced the potency of L-Quis on E325I. (D) The fold-change in EC_{50} for activation of WT mGluR1α, D322I and E325I by L-Quis upon increasing $[Ca^{2+}]_o$ from nominal zero to 1.8 mM. The-fold decreases in the EC_{50} values for WT mGluR1α, D322I and E325I are 4.6, 3.9 and 2.7, respectively. (E) [^{3}H]-L-Quis binds to WT mGluR1α in the absence of $[Ca^{2+}]_o$, but mutations in the $[Ca^{2+}]_o$-binding site decrease L-Quis-binding. D318I eliminates L-Quis-binding, while D322I and E325I still retain L-Quis binding. An additional 5 mM $[Ca^{2+}]_o$ enhanced L-Quis binding to WT mGluR1α (p=0.031) and D322I, whereas this $[Ca^{2+}]_o$ effect was abolished in E325I. The binding buffer used was hypotonic buffer (N=3). (*p<0.05)

FIGURE 4. **Effects of (s)-MCPG on the response of WT mGluR1α to L-Glu and $[Ca^{2+}]_o$.** (A) Increasing the concentration of (s)-MCPG inhibits mGluR1α in the presence of 5 μM L-Glu, and 1.5 mM (s)-MCPG entirely blocks the activation of the receptor by L-Glu. (s)-MCPG attenuates the responsiveness of mGluR1α to 5 mM $[Ca^{2+}]_o$, and 2.0 mM MCPG does not completely inhibit the capacity of the receptor to sense $[Ca^{2+}]_o$. (B) 0.5 mM (s)-MCPG competitively inhibits L-Glu-induced $[Ca^{2+}]_i$ responses. Lineweaver-Burk plot analysis indicates that (s)-MCPG competes with L-Glu (inset). (C) 0.5 mM (s)-MCPG inhibits low $[Ca^{2+}]_o$-induced $[Ca^{2+}]_I$ responses, but high $[Ca^{2+}]_o$ restores the response of the receptor. (N=3).

FIGURE 5. **Effects of CPCCOEt on the responses of mGluR1α to L-Glu and $[Ca^{2+}]_o$.** (A) In the presence of 10 or 40 μM CPCCOEt, the sensitivity of mGluR1α to L-Glu was reduced. The maximal response was reduced to about 50% in the presence of 40 μM CPCCOEt. (B) The $[Ca^{2+}]_o$ sensitivity of wild type mGluR1a was reduced by the addition of 5 or 40 μM CPCCOEt. $[Ca^{2+}]_i$ was measured using Fura-2 AM in the absence (solid dots) or presence of 5 μM (solid square) or 40 μM (empty circle) CPCCOEt. In the cells inhibited by CPCCOEt (5 or 40 μM), increasing $[Ca^{2+}]_o$ counteracts the inhibitory effects of CPCCOEt. HEK293 cells transiently

16

expressing WT mGluR1α were mounted on coverslips, and the $[Ca^{2+}]_i$ change indicated by fura-2AM was collected. (N=3).

FIGURE 6. **$[Ca^{2+}]_o$ and Ro 67-4853 co-activate mGluR1α**. HEK293 cells growing on coverslips were transiently transfected with wild type mGluR1α. After dye loading, the cells were pre-incubated in 10 mM HEPES, 140 mM NaCl, 5 mM KCl, 0.55 mM $MgCl_2$, 0.5 mM $CaCl_2$ and 5 nM Ro 67-4853 (pH 7.4) for 10 min. (**A**) 10 or 100 nM Ro 67-4853 enhances the L-Glu sensitivity of mGluR1α. (**B**) 30 or 300 nM Ro 67-4853 increases the $[Ca^{2+}]_o$ sensitivity of mGluR1α (**C**) Addition of $[Ca^{2+}]_o$ and Ro 67-4853 to the cells. Ro 67-4853 displayed activity on mGluR1α in the presence of 0.5 mM $[Ca^{2+}]_o$, while 1.8 mM $[Ca^{2+}]_o$ enhanced its potency. (* p < 0.05; ** P < 0.01; # P = 0.05)

FIGURE 7. **E325I retains the enhanced responsiveness of the receptor to 10 μM Ro 67-4853 in the presence of L-Glu but loses its potentiation by $[Ca^{2+}]_o$.** (**A**) Addition of 30 μM L-Glu increases the Ro 67-4853 sensitivity of E325I in the presence of 1.8 mM $[Ca^{2+}]_o$ (P=0.014). (**B**) E325I responds to 10 μM Ro 67-4853 in the absence of both $[Ca^{2+}]_o$ and L-Glu. Increasing $[Ca^{2+}]_o$ from 0 to 5.0 mM had no effect on the response of E325I to Ro 67-4853, while the activity of WT mGluR1 to Ro 67-4853 was progressively enhanced to increases in the $[Ca^{2+}]_i$ response of E325I (N=3) (*p < 0.05). Both WT mGluR1 and E325I have stronger responses while exposing to 10 and 20 μM Ro 67-4853 in the presence of 5 mM Ca^{2+}, respectively. (*P<0.05)

Table 1. **Mutations in the $[Ca^{2+}]_o$-binding site perturb the correlated motions between the $[Ca^{2+}]_o$-binding site and the L-Glu-binding site of mGluR1α**

	D318	D322	E325
WT	W110, S165, T188, D208, Y236, D318, R323	W110, S165, T188, Y236, D318, R323	R323
D318I	D208, G293, D318, R323	G293, D318, R323	G293, D318, R323
D322I	Y74, W110, G293, D318, R323, K409	D318, R323	Y74, G293, D318, R323
E325I	Y236, G293, D318, R323	G293, D318, R323	G293, D318, R323

*Based on the correlation map shown in Figure 2, there is correlated motion between the reported L-Glu-binding pocket and the $[Ca^{2+}]_o$-binding site (D318, D322 and E325). The residues with absolute correlation values greater than 0.3 are listed in this table. Of note, WT has five residues (shadowed residues are not included because they reside in the same loop as the $[Ca^{2+}]_o$-binding site and thus would have same motion) in the L-Glu-binding site that correlate with $[Ca^{2+}]_o$-binding 1, while there are only correlations between two residues in variants D318I and E325I, and four in D322I. Shadowed residues are in the same loop as the $[Ca^{2+}]_o$-binding site, and they have same movements as the $[Ca^{2+}]_o$-binding site by default.

Table 2. **Effects of $[Ca^{2+}]_o$ on the responses of WT-mGluR1α and variants with mutations $[Ca^{2+}]_o$-binding site 1 to L-Quis.**

$[Ca^{2+}]_i$ response increase induced by increasing L-Quis via WT-mGluR1a, D322I and E325I were measured in both Ca^{2+}-free saline and buffer with physiological Ca^{2+}.

$[Ca^{2+}]_o$ concentration (mM)	WT			D322I			E325I		
	EC_{50} (nM)	Maximal Response (%)[a]	Fold decrease in EC_{50}	EC_{50} (nM)	Maximal Response (%)[a]	Fold decrease in EC_{50}	EC_{50} (nM)	Maximal Response (%)[a]	Fold decrease in EC_{50}
0	12.8	37 ±4	4.6	12.4	80 ±16	3.9	20.6	60 ±8	2.7
1.8	2.8	37 ±5		3.2	96 ±21		7.6	88 ±8	
K_D (mM)[b]	0.3			0.6			>20.0		

a. The maximal responses are normalized to the maximal response of WT mGluR1α to L-Glu

b. $[Ca^{2+}]_o$-binding affinity of mGluR1α in the presence of 30 nM [3H]-L-Quis (E325I with 300 nM [3H]-L-Quis)

Table 3. **Addition of 0.5 mM (s)-MCPG decreases the responses of mGluR1α to $[Ca^{2+}]_o$ and L-Glu.**
The $[Ca^{2+}]_i$ response to $[Ca^{2+}]_o$ and L-Glu in the absence or presence of 0.5 mM (s)-MCPG were obtained by measuring the ratiometric change of Fura-2 AM fluorescence.

(s)-MCPG (mM)	Response to $[Ca^{2+}]_o$			Response to L-Glu	
	EC_{50} (mM)	n_{Hill}	Maximal Response[a]	EC_{50} (μM)	Maximal Response[a]
0	3.5	6.4	85 ±2	1.7	100 ±2
0.5	6.0	2.6	67 ±2	3.7	97 ±5

a. The maximal responses are normalized to the maximal response of WT mGluR1α to L-Glu

Table 4. **The effects of CPCCOEt on the responsiveness of mGluR1α to L-Glu and $[Ca^{2+}]_o$ (N=3).**
WT mGluR1α was incubated with increasing concentrations of $[Ca^{2+}]_o$ with either 0, 5 or 40 nM CPCCOEt (left side) or to increasing concentrations of L-Glu in the presence of the indicated fixed concentrations of CPCCOEt.

CPCCOEt Conc. (nM)	Response to $[Ca^{2+}]_o$			Response to L-Glu	
	EC_{50} (mM)	n_{Hill}	Maximal Response (%)[a]	EC_{50} (μM)	Maximal Response (%)[a]
0	3.5	6.4	85 $\pm$2	1.7	100 $\pm$2
5	7.6	1.3	75 $\pm$3	-	-
10	-	-	-	5.2	44 $\pm$8
40	14.7	1.1	60 $\pm$3	10.1	30 $\pm$10

a. The maximal responses are normalized to the maximal response of WT mGluR1α to L-Glu

Table 5. **$[Ca^{2+}]_o$ effects on modulation of mGluR1α by Ro 67-4853 (N=3).**

WT mGluR1α was incubated with increasing concentrations of Ro 67-4583 with either 0.5 or 1.8 mM $[Ca^{2+}]_o$ (left side) or to increasing concentrations of $[Ca^{2+}]_o$ in the presence of the indicated fixed concentrations of Ro 67-4583.

$[Ca^{2+}]_o$ Conc.	EC_{50}[a]	Max. Res.[c]	Ro 67-4853 Conc.	EC_{50}[b]	Max. Res.[c]
0.5 (mM)	20.7 (nM)	50 ±8	0 (nM)	3.5 (mM)	85 ±2
1.8 (mM)	10.0 (nM)	59 ±4	30 (nM)	2.1 (mM)	83 ±6
			300 (nM)	0.7 (mM)	83 ±2

a. Refers to EC_{50} of Ro 67-4853
b. Refers to EC_{50} of Ca^{2+}
c. The maximal responses are normalized to the maximal response of WT mGluR1α to L-Glu.

Table 6. **Analysis of ligand interaction by LPC server**

PDB files bound with L-Quis, L-Glu and (s)-MCPG were analyzed by the online LPC server. The output, including distance, surface interacting and atom number contributing to binding, were as summarized below.

Residue Number	Distance (Å)			Surface (Å^2)			Number of contacts		
	L-Quis	L-Glu	(s)-MCPG	L-Quis	L-Glu	(s)-MCPG	L-Quis	L-Glu	(s)-MCPG
Y74	2.7	2.5	2.6	29.4	37.3	46.7	9	7	7
R78	-	5.1	5.5	-	0.3	1.6	-	1	1
W110	3.6	3.9	3.9	37.1	20.2	28.5	8	8	9
G163	3.7	3.9	4.8	8.5	8.7	2.7	2	2	1
S164	3.1	3.5	4.8	23.6	7.3	8.3	3	3	4
S165	3.0	2.7	2.9	35.7	43.7	46.6	4	4	7
S166	-	-	4.4	-	-	0.7	-	-	1
S186	3.5	2.8	3.7	26.5	29.3	27.2	5	5	10
A187	3.6	3.3	-	1.6	1.6	-	1	1	-
T188	3.8	2.9	3.2	3.9	27.9	27.0	2	4	3
S189	-	-	5.0	-	-	2.7	-	-	3
D208	-	-	4.8	-	-	0.9	-	-	2
Y236	3.6	3.4	4.2	42.9	40.4	46.7	10	14	13
E292	3.9	5.0	-	22.2	5.0	-	7	5	-
G293	3.7	5.1	-	25.9	1.2	-	3	1	-
M294	4.6	-	-	3.3	-	-	2	-	-
D318	3.7	2.8	5.0	19.8	31.3	9.5	3	2	4
G319	3.4	3.7	6.2	19.2	21.4	1.3	4	3	2
R323	3.5	3.7	6.1	15.5	10.4	3.1	3	1	1
K409	2.8	3.6	3.1	32.2	23.9	30.0	3	4	4

"-" means no contacts

Figure 1

A

Figure 2

Figure 3

Figure 4

Figure 5

A

B

Figure 6

Figure 7

30

Extracellular calcium modulates actions of orthosteric and allosteric ligands on metabotropic glutamate receptor 1 alpha

Jason Y. Jiang, Mulpuri Nagaraju, Rebecca C. Meyer, Li Zhang, Donald Hamelberg, Randy A. Hall, Edward M. Brown, P. Jeffrey Conn and Jenny J. Yang

Alerts:
- When this article is cited
- When a correction for this article is posted

Click here to choose from all of JBC's e-mail alerts

This article cites 0 references, 0 of which can be accessed free at
http://www.jbc.org/content/early/2013/11/26/jbc.M113.507665.full.html#ref-list-1